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Spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are severe
nervous system diseases characterized by the degeneration of lower motor neurons.
They share a number of additional pathological, cellular, and genetic parallels suggesting
that mechanistic and clinical insights into one disorder may have value for the other.
While there are currently no clinical ALS gene therapies, the splice-switching antisense
oligonucleotide, nusinersen, was recently approved for SMA. This milestone was
achieved through extensive pre-clinical research and patient trials, which together have
spawned fundamental insights into motor neuron gene therapy. We have thus tried to
distil key information garnered from SMA research, in the hope that it may stimulate a
more directed approach to ALS gene therapy. Not only must the type of therapeutic
(e.g., antisense oligonucleotide vs. viral vector) be sensibly selected, but considerable
thought must be applied to the where, which, what, and when in order to enhance
treatment benefit: to where (cell types and tissues) must the drug be delivered and
how can this be best achieved? Which perturbed pathways must be corrected and can
they be concurrently targeted? What dosing regime and concentration should be used?
When should medication be administered? These questions are intuitive, but central
to identifying and optimizing a successful gene therapy. Providing definitive solutions to
these quandaries will be difficult, but clear thinking about therapeutic testing is necessary
if we are to have the best chance of developing viable ALS gene therapies and improving
upon early generation SMA treatments.
Keywords: adeno-associated virus (AAV), ALS, antisense oligonucleotide (ASO), motor neuron disease (MND),
neurodegeneration, neurotrophic factor, SMA, survival motor neuron (SMN)
Abbreviations: AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis; ASO, antisense oligonucleotide; BBB,
blood-brain barrier; BDNF, brain-derived neurotrophic factor; BSCB, blood-spinal cord barrier; C9ORF72, chromosome
9 open reading frame 72; CNS, central nervous system; CNTF, ciliary-derived neurotrophic factor; CPP, cell-penetrating
peptide; CSF, cerebrospinal fluid; EMA, European Medicines Agency; fALS, familial ALS; FDA, Food and Drug
Administration; FTD, frontotemporal dementia; FUS, fused in sarcoma; HGF, hepatocyte growth factor; IGF-1, insulin-
like growth factor; iPSC, induced pluripotent stem cell; ISS-N1, intronic splicing silencer N1; LMN, lower motor neuron;
LV, lentivirus; MND, motor neuron disease; NMJ, neuromuscular junction; RNAi, RNA interference; sALS, sporadic ALS;
scAAV, self-complementary AAV; SMA, spinal muscular atrophy; SMN, survival motor neuron; snRNA, small nuclear RNA;
snRNP, small nuclear ribonucleoprotein; SOD1, superoxide dismutase 1; SSO, splice-switching oligonucleotide; TARDBP,
transactive-region DNA binding protein; TLS, translocated in liposarcoma; UMN, upper motor neuron; VEGF, vascular
endothelial growth factor.
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INTRODUCTION
Spinal muscular atrophy and amyotrophic lateral sclerosis are
two devastating neurological conditions with the common
pathological hallmark of motor neuron degeneration, ultimately
leading to muscle wasting and death. While etiology, age of onset,
progression, and survival outcomes can drastically differ between
the diseases, they share a number mechanistic parallels; thus,
experimental and clinical insights into the one disorder may
prove useful for the other.
It is an exciting time for the SMA community as the first
treatment, an ASO gene therapy called nusinersen, was approved
in the US by the FDA on 23rd December, 2016. Nusinersen
subsequently received marketing authorisation in the EU from
the EMA in June, 2017. This starkly contrasts with the situation
for ALS, where clinically viable gene therapies are currently non-
existent, while recent trials of chemically diverse drugs have
failed to live up to expectations piqued by mouse experiments.
Although there are numerous complications in treating ALS
that do not pertain to SMA, a number of fundamental lessons
have been learnt from the gamut of pre-clinical research and
clinical trials of SMA gene therapies that could prove useful in
galvanizing a targeted approach to ALS gene therapy design and
development.
In this review, we will first provide introductions to SMA,
ALS, and commonalities between the two, and follow this with
an overview of gene therapies tested in clinical trials for both
diseases. We use the term gene therapy to encompass both virus-
mediated gene transfer and ASO gene targeting. Rather than
provide an exhaustive review of all SMA and ALS gene therapy
research, which has been collectively well covered (Federici and
Boulis, 2012; Nizzardo et al., 2012; Mulcahy et al., 2014; Scarrott
et al., 2015; Singh N.N. et al., 2017), we will then outline some
of the major issues that SMA gene therapy has encountered, try
to distil key, emergent concepts, and frame this in the context of
ALS in order to provide possible future experimental directions.




Spinal muscular atrophy (SMA) is a monogenic neuromuscular
disorder affecting ≈1 in 8,500–12,500 newborns, and is the
most common genetic cause of infant mortality (Verhaart et al.,
2017a,b). Patients present with severe muscle weakness and
atrophy, predominantly in proximal (e.g., trunk) muscles, due
to degeneration of LMNs of the spinal cord ventral horn.
Pathology in additional cells and tissues can be observed in
more severe manifestations of the disease, which has considerable
implications for treatment (Hamilton and Gillingwater, 2013).
SMA is caused by reduced levels of SMN protein (Lefebvre
et al., 1995), which is found in the nucleus and cytoplasm of
almost all cells, and plays a vital, canonical, housekeeping role
in spliceosome assembly (Fischer et al., 1997; Liu et al., 1997;
Pellizzoni et al., 2002), amongst other functions (Singh R.N. et al.,
2017). Specifically, as part of the multi-protein SMN complex,
SMN directs the efficient cytoplasmic assemblage of small nuclear
RNAs (snRNAs) with Sm protein rings leading to the formation
of small nuclear ribonucleoproteins (snRNPs) (Gruss et al., 2017).
After nuclear-import, snRNPs function in the catalytic removal
of introns from pre-mRNA transcripts in the process of splicing
(Pellizzoni et al., 2002). Despite having a good understanding
of this and other functions of SMN, the precise cause of the
largely selective LMN death remains to be fully resolved. It
is likely that a combination of multiple mechanisms account
for this vulnerability, including mis-splicing of LMN-specific
genes, SMN levels being lower in LMNs than other cell types,
and disturbance of a possible non-canonical, LMN-specific SMN
function (Figure 1A) (Tisdale and Pellizzoni, 2015; Jablonka and
Sendtner, 2017; Tu et al., 2017).
Survival motor neuron is encoded by two almost identical
genes, SMN1 and its paralogue SMN2 (Figure 1B) (Lefebvre
et al., 1995). A single functioning SMN1 allele produces sufficient
protein for LMNs to remain healthy – as demonstrated by the
≈1 in 40–60 people with one functional copy of SMN1 (i.e.,
SMA carriers) showing no clinical phenotype. However, due to
a single nucleotide distinction (synonymous C-to-T alteration 6
nucleotides into exon 7), exon 7 of SMN2 is aberrantly spliced
≈90% of the time (creating truncated, non-functional SMN17
protein) and is therefore capable of producing only ≈10% of
the full-length SMN made by SMN1 (Figure 1B) (Lorson et al.,
1999; Monani et al., 1999). Thus, when protein production
from SMN1 is impaired, as it is in SMA patients, SMN2 can
only partially compensate. SMN is highly conserved throughout
evolution, permitting modeling of reduced SMN function in
diverse organisms (Grice et al., 2011; Patten et al., 2014; Duque
et al., 2015); however, all models naturally only possess an
ortholog of SMN1, but not SMN2. To better mimic disease
genetics, many transgenic mice have been engineered to express
diminished SMN levels (Sleigh et al., 2011), the most frequently
used being the SMN17 mouse, which combines human SMN2
and SMN17 transgenes on a null Smn background (Le et al.,
2005). Relative genomic instability of the region (5q13) is believed
to be the reason for the recent evolutionary duplication of
the SMN locus (Rochette et al., 2001), and may also account
for there being considerable variability in SMN2 copy number
within the population. The number of SMN2 genes a patient
with SMA possesses has important ramifications for disease
severity, as more SMN2 copies can produce more SMN, which
correlates with diminished symptom severity (Lefebvre et al.,
1997). Although not predictive at the individual level, in a
population, SMN2 copy number thus inversely correlates with
SMA severity (McAndrew et al., 1997), which is categorised into
four principal post-natal types (I-IV) based on age of onset and
motor milestones achieved (Munsat and Davies, 1992).
Manifesting at or before 6 months and radically limiting life
expectancy (<2 years), type I SMA (a.k.a. Werdnig-Hoffmann
disease) is the most severe and frequently diagnosed form of
SMA, and prevents children from ever being able to sit unaided.
Infant death is usually caused by respiratory complications,
although with specialized care, lifespan can be artificially
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FIGURE 1 | Spinal muscular atrophy mechanisms and genetics. (A) Multiple hypothetical mechanisms have been suggested to cause or contribute to the selective
LMN degeneration of SMA, the three most plausible of which are that: #1 SMN reduction impairs splicing fidelity of a LMN-specific gene(s). E, exon; I, intron; #2 less
SMN is available in LMNs than other cells due to a negative feedback loop, more prominent in LMNs, in which low SMN levels impair further SMN2 exon 7 inclusion
(see B) exacerbating SMN reduction. 17, truncated SMN mRNA; FL, full-length SMN mRNA; FL-SMN, full-length SMN protein; snRNPs, small nuclear
ribonucleoproteins; and #3 a non-canonical, LMN-specific function of SMN is perturbed, for instance anterograde axonal transport of mRNA. (B) A single copy of
SMN1 produces enough SMN protein for motor neurons to thrive and for SMA disease carriers to remain healthy. Due to a single base pair distinction (C-to-T
transition in exon 7), exon 7 is mis-spliced out of ≈90% of SMN2 transcripts, resulting in a truncated, less stable, and only partially functional protein. This figure has
been adapted from Neuromuscular Disorders, 23, Sleigh et al., 2013 Spinal muscular atrophy at the crossroads of basic science and therapy, 96, Copyright (2013),
with permission from Elsevier.
extended for long periods. Type II SMA (Intermediate/Dubowitz
Syndrome) presents between 7 and 18 months, permits unaided
sitting but not walking, and has survival probabilities of ≈93%
and ≈52% at 20 and 40 years, respectively (Farrar et al.,
2013). Type III SMA (Kugelberg-Welander disease) limits motor
function and has an onset > 18 months, but before adolescence,
while type IV SMA (adult-onset) typically manifests in the second
or third decade of life with mild-to-moderate muscle weakness,
but generally no respiratory issues.
Amyotrophic Lateral Sclerosis
With a lifetime risk of ≈1 in 400 (Alonso et al., 2009), ALS,
also called MND and Lou Gehrig’s disease, is a fatal, progressive,
mostly adult-onset disorder of both LMNs and UMNs.
Neurodegeneration is observed in the cortex, corticospinal tracts,
brainstem, and spinal ventral horn neurons and is accompanied
by neuroinflammation (Brown and Al-Chalabi, 2017). Starting
focally and spreading, this causes major symptoms of muscle
weakness and fasciculations with subsequent atrophy, leading
to death usually through respiratory failure within 3 years of
diagnosis (Chiò et al., 2009). ALS also shares neuropathological
and genetic features with FTD (Morita et al., 2006; Neumann
et al., 2006; Vance et al., 2006), with approximately half of ALS
patients showing some level of cognitive impairment (Ringholz
et al., 2005). This has led to ALS and FTD being considered as part
of the same clinicopathological spectrum (Ling et al., 2013). ALS
patients display considerable symptom heterogeneity inclusive
of age, site of disease onset, the rate and pattern of spread,
and relative LMN/UMN involvement (Kiernan et al., 2011).
ALS can therefore be sub-categorized based on several clinical
and neuropathological criteria (Al-Chalabi and Hardiman, 2013;
Bäumer et al., 2014). Given this variability, the ALS diagnosis
is challenging, particularly during early disease stages (Byrne
et al., 2012). The mean time from first noticeable symptom to
clinical diagnosis is consequently (≈1 year). Contributing to
this delay, no diagnostic or prognostic biomarkers are yet in
regular clinical use for ALS, which also impacts the assessment
of therapeutic efficacy in patient trials (Rosenfeld and Strong,
2015). Nevertheless, a number of prospective biomarkers have
recently been identified, including the neurotrophin receptor
p75NTR extracellular domain in urine (Shepheard et al., 2017) and
neurofilament chains in plasma (Lu et al., 2015) and CSF (Oeckl
et al., 2016).
ALS has traditionally been classified into clinically
indistinguishable sporadic (sALS) and familial (fALS) forms;
sALS occurs without family history of the disease and represents
the majority of cases (≈90%), whereas fALS contributes ≈10%
of patients and is genetically inherited, predominantly in an
autosomal, dominant fashion. The pathological and clinical
variability of the disease has led to the idea that, in addition to
being on a continuum with FTD, ALS itself may not be a single
disorder, but a syndrome (Turner et al., 2013). Consistent with
this, aberrations in over 25 genetic loci have been reproducibly
linked with the ALS phenotype (Brown and Al-Chalabi, 2017),
with new genes constantly being identified (Freischmidt et al.,
2015; Brenner et al., 2016; Mackenzie et al., 2017). The four
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most common mutations are large, intronic, hexanucleotide
repeat (G4C2) expansions in chromosome 9 open reading frame
72 (C9orf72) (DeJesus-Hernandez et al., 2011; Renton et al.,
2011), and dominant mutations in superoxide dismutase 1
(SOD1) (Rosen et al., 1993), transactive-region DNA binding
protein (TARDBP encoding TDP-43) (Sreedharan et al., 2008),
and fused in sarcoma (FUS, a.k.a. translocated in liposarcoma,
TLS) (Kwiatkowski et al., 2009; Vance et al., 2009). Mutations
in C9orf72 are the most common genetic cause of ALS hitherto
identified, accounting for ≈40% of fALS and ≈7% of sALS (in
populations of European ancestry) (Renton et al., 2014). The
exact function of the encoded protein remains unclear, but it
appears that it may be important in membrane trafficking and
autophagy (Nassif et al., 2017). Encoding a Cu/Zn dismutase
enzyme that provides defense against toxic superoxide free
radicals, SOD1 was the first gene linked to ALS (Rosen et al.,
1993), and its mutation is responsible for ≈12% and ≈1%
of fALS and sALS patients, respectively (Renton et al., 2014).
As a consequence of its early identification and the rapid
generation of the SOD1G93A mouse model (Gurney et al., 1994),
research into SOD1 has shaped much of the ALS research
landscape. Nevertheless, many other cellular and animal models
are now available for different genetic forms of the disease
(van Damme et al., 2017). TARDBP and FUS encode nucleic
acid-binding proteins that predominantly reside in the nucleus,
and are involved in multiple aspects of RNA processing, such as
transcription and splicing. Mutations in these two genes each
account for ≈4% of fALS and ≈1% of sALS patients (Renton
et al., 2014). Despite significant progress in our understanding
of the molecular pathogenesis linked to these four genes, it
has not been fully resolved as to whether pathology is solely
caused by a toxic gain-of-function or whether there are also
loss-of-function effects (Lee et al., 2012; Bunton-Stasyshyn et al.,
2015; Scekic-Zahirovic et al., 2016; Moens et al., 2017).
Causative genetic mutations have been identified in only
≈68% and≈11% of fALS and sALS patients, respectively (Renton
et al., 2014). This lack of an obvious genetic cause in most
ALS patients, along with incomplete penetrance in several fALS
pedigrees (Cirulli et al., 2015; Freischmidt et al., 2015), suggests
that ALS may most frequently arise from additive effects of
an assortment of predispositions and insults (Al-Chalabi and
Hardiman, 2013). Indeed, rare variants in many other genes
have been identified as ALS risk factors (van Rheenen et al.,
2016), as have particular environmental stimuli (Martin et al.,
2017a). Moreover, twin studies indicate that sALS heritability in
the absence of a family history of the disease is still ≈60% (Al-
Chalabi et al., 2010). Together, these data indicate that ALS may
develop through a multi-step process in which aging is a critical
component (Al-Chalabi et al., 2014), involving varying degrees
of heritability and diverse, but inter-related, functional pathways
that, upon dysregulation, yield motor neuron degeneration
(Turner et al., 2013). This makes the strict fALS/sALS distinction
an artificial dichotomy (Talbot, 2011), and presents obvious and
considerable hurdles for the identification and development of
viable therapeutic strategies for the disease.
Intrinsic motor neuron defects and non-cell autonomous
toxicities in associated cell types (e.g., glia, interneurons)
contribute to ALS (Ilieva et al., 2009; Ramírez-Jarquín et al.,
2014; Puentes et al., 2016), but similar to SMA, the exact
mechanisms underpinning motor neuron death, and their
relative vulnerability-resistance axis (Nijssen et al., 2017), remain
to be elucidated. Nevertheless, given the known functions of
major ALS genes, altered RNA processing, nuclear protein
mishandling/protein quality control, and impaired cytoskeletal
dynamics appear to be three inter-related central themes (Bäumer
et al., 2010; Brown and Al-Chalabi, 2017). Congruously, the vast
majority of both sALS and fALS patients display cytoplasmic
depositions of aggregated proteins, the main component of which
is TDP-43 (Neumann et al., 2006), albeit with varied cellular
distributions (Al-Sarraj et al., 2011). However, these inclusions
conspicuously lack TDP-43 in SOD1-linked (Mackenzie et al.,
2007) and FUS-linked (Vance et al., 2009) ALS. Additional
defects in diverse cellular processes have been implicated in ALS
including excitotoxicity, oxidative stress, altered oligodendrocyte
function, axonal transport defects, mitochondrial malfunction,
and neurotrophic factor deficits (reviewed in Kiernan et al., 2011;
Taylor et al., 2016). It remains unclear as to which, if any, of these
phenomena play a primary role in disease pathogenesis, rather
than simply being non-specific consequences of a dysfunctional
system. Moreover, it should be noted that most of these
pathologies were identified using SOD1G93A mice, which have
their limitations for modeling all forms of ALS (Kiernan et al.,
2011; Turner et al., 2013). To overcome this, numerous transgenic
mouse models of ALS have been developed (van Damme
et al., 2017), and strict guidelines for their use in pre-clinical
therapeutic trials have been created to limit irreproducibility
(Ludolph et al., 2010).
SMA and ALS: A Common Mechanism?
SMA and ALS share a propensity for LMN degeneration leading
to muscle wasting and atrophy. A number of key cellular and
molecular parallels between the two diseases have also been
reported (Cauchi, 2014; Gama-Carvalho et al., 2017; Hensel
and Claus, 2017). The causative gene in SMA encodes a widely
expressed, multi-functional protein important for fundamental
cellular processes including pre-mRNA splicing (Fischer et al.,
1997; Liu et al., 1997; Pellizzoni et al., 2002), transcription
(Pellizzoni et al., 2001), and mRNA transport and stability
(Rossoll et al., 2003; Zhang et al., 2003). While the importance
of protein quality control to ALS should not be underestimated,
some of the major genetic contributors to the disease, perhaps
with the exception of C9ORF72, are also found ubiquitously
and perform similar functions vital to RNA processing and
maturation (Bäumer et al., 2010). For instance, both TDP-43 and
FUS are involved in splicing (Zhou et al., 2002; Polymenidou
et al., 2011) and transcription (Uranishi et al., 2001), and, along
with SOD1, are thought to be important for the transport and
stability of mRNA (Fujii and Takumi, 2005; Lu et al., 2007; Strong
et al., 2007). Recently, dominant mutations in T-cell restricted
intracellular antigen 1 (TIA1), which is an RNA-binding protein
involved in SMN2 exon 7 splicing (Singh et al., 2011), were shown
to play a causative role in ALS (Mackenzie et al., 2017), while
TIA1 knockout modifies phenotypes of mild male SMA mice
(Howell et al., 2017). Furthermore, wild-type TDP-43 and FUS
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interact with SMN (Wang I.-F. et al., 2002; Yamazaki et al., 2012;
Groen et al., 2013; Sun et al., 2015), and all three proteins have
been implicated in the formation of stress granules (Hua and
Zhou, 2004; Andersson et al., 2008; Colombrita et al., 2009), as
has C9ORF72 (Maharjan et al., 2017).
Comparable in structure to stress granules, Gemini of Cajal
bodies (a.k.a. gems) are membrane-free, nuclear conglomerates
of SMN and associated proteins (Liu and Dreyfuss, 1996),
the number of which correlates with SMN availability and is
thus inversely related to SMA severity (Lefebvre et al., 1997;
Feng et al., 2005). Numerous studies have shown that gem
distribution/number is also affected in SOD1-, FUS-, and TDP-
43-associated ALS patient tissue, mice, and cellular models (Shan
et al., 2010; Gertz et al., 2012; Kariya et al., 2012; Yamazaki
et al., 2012; Ishihara et al., 2013; Tsuiji et al., 2013; Sun et al.,
2015), although this pattern was not observed in sALS patient
fibroblasts (Kariya et al., 2014b). Nonetheless, SMN protein levels
are reduced in sALS patient spinal cords (Turner et al., 2014)
and pre-symptomatically in SOD1G93A mouse spinal cords, while
a 50% reduction in SMN exacerbates the SOD1G93A phenotype
(Turner et al., 2009). Furthermore, one study showed that ALS
patients on average possess fewer SMN2 copies, while having
one SMN1 copy is associated with increased ALS susceptibility
(Veldink et al., 2005), although this link is not straightforward
(Blauw et al., 2012; Corcia et al., 2012; Wang X.-B. et al.,
2014). Nevertheless, SMN upregulation protects against mutant
SOD1-induced cell death in an immortalized motor neuronal
cell line (NSC-34) (Zou et al., 2007), rescues mutant FUS-
mediated axonal defects in primary cortical neurons (Groen
et al., 2013), and can improve survival of iPSC-derived motor
neurons differentiated from SOD1 and TDP-43 ALS patient
fibroblasts (Rodriguez-Muela et al., 2017). Moreover, neuronal
SMN overexpression aids motor neuron survival and delays
symptom onset in SOD1G85A, SOD1G93A, and TDP-43A315T mice
(Kariya et al., 2012; Turner et al., 2014; Perera et al., 2016).
Survival of both SOD1 models was unaffected, but female TDP-
43 mice displayed a significant extension. SMN may in fact serve
as a general survival factor for motor neurons, as it is required
to facilitate neuromuscular regeneration post-sciatic nerve crush
in adult mice (Kariya et al., 2014a). In addition, low SMN levels
in healthy iPSC-derived motor neurons correlate with greater
cell death, and SMN upregulation promotes increased survival of
control motor, but not cortical, neurons (Rodriguez-Muela et al.,
2017).
These commonalities between SMA and ALS suggest that
a shared mechanism could underlie at least certain aspects of
the two diseases. Perhaps the most likely cause of the link is
sequestration of SMN and/or splicing factors into cytoplasmic
inclusions by mutant ALS gene products, resulting in defective
RNA homeostasis. Indeed, ALS-associated mutations in FUS can
enhance its association with SMN and impinge upon its axonal
localization (Groen et al., 2013; Sun et al., 2015). Additionally,
mutant FUS and C9orf72 expansion can affect splicing factor
distribution (Gerbino et al., 2013; Lee et al., 2013; Mori et al.,
2013; Yu et al., 2015; Reber et al., 2016), as can homozygous
overexpression of human wild-type FUS in mice (Mirra et al.,
2017). Widespread splicing defects are unlikely to account for the
motor neuron selectivity observed in SMA (Bäumer et al., 2009);
however, the early and specific mis-splicing of a few crucial motor
neuron-expressed genes may be particularly relevant to disease
pathogenesis (Zhang et al., 2013; Sleigh et al., 2014). Splicing
impairments have also been reported in ALS models and patient
tissue (Chabot and Shkreta, 2016; Conlon et al., 2016); it is thus
plausible that early splicing perturbations in a common set of
critical genes could explain some of the shared pathomechanisms
of SMA and ALS. Indeed, considerable overlap in alternative
splicing events between SMA models and human FUS-expressing
mice were recently reported, including in a number of ALS-
pertinent genes (Mirra et al., 2017). These discoveries and the
mechanistic intersection of ALS with SMA, suggest that gene
therapy strategies able to augment SMN levels may be beneficial
to both fALS and sALS patients, perhaps not in isolation, but as
part of a combinatorial approach.
CLINICAL GENE THERAPY FOR MOTOR
NEURON DISEASES
SMA: SMN Restoration Is Key
The genetic lesion underlying SMA causes diminished SMN
protein levels; in theory, treatment is thus simple – replenish
SMN. Small molecule, SMN2 splice-modifying drugs, such as
RG7916 (Roche) and LMI070 (Novartis), that augment SMN and
SMN-independent, neuroprotection strategies are being pursued
(Scoto et al., 2017), but SMN gene therapies are currently
proving more clinically promising. In the last decade, we have
rapidly transitioned from several early ineffective SMA patient
trials (Fuller et al., 2010), to the recent regulatory approval of
nusinersen for the treatment of SMA types I-IV.
Nusinersen (a.k.a. Spinraza, IONIS-SMNRx, ISIS-SMNRx, ISIS
396443, and ASO-10-27) is an ASO developed through work of
numerous laboratories and a collaboration between Biogen Idec
and Ionis Pharmaceuticals (formerly Isis Pharmaceuticals). ASOs
are short (15–25 nucleotides), synthetic, single-stranded DNA
or RNA sequences that specifically bind to target pre-mRNA
or mRNA sequences, impacting gene expression. ASOs that
specifically modulate splicing are also called SSOs. Importantly
for diseases affecting the nervous system, ASOs distribute widely
when injected into the CSF, do not require carrier molecules, and
have relatively long half-lives (Geary et al., 2015). Nusinersen,
which is delivered via single intrathecal injections directly into
the CSF (i.e., by lumbar puncture) (Chiriboga et al., 2016;
Haché et al., 2016), is a 2′-O-(2-methoxyethyl) modified ASO
complementary to the ISS-N1 found in intron 7 of SMN2
pre-mRNA (Singh et al., 2006; Hua et al., 2008). Specific
ASO/pre-mRNA hybridisation restricts exon 7 mis-splicing,
thereby increasing the amount of functional SMN made by SMN2
(Figure 2A). A considerable amount of work in SMA mice
provided substantial evidence for in vivo efficacy of nusinersen
(Singh N.N. et al., 2017), leading to a series of stratified clinical
trials (Chiriboga et al., 2016; Finkel et al., 2016, 2017). A pre-
specified interim analysis from a randomized, double-blind, sham
procedure-controlled phase III trial in SMA type I patients
called ENDEAR (ClinicalTrials.gov Identifier: NCT02193074),
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FIGURE 2 | Antisense oligonucleotide targeting of SMN2 splicing and SOD1 translation. (A) Nusinersen is a SSO complementary to an intronic sequence in SMN2
called ISS-N1, which is the main inhibitory element for exon 7 splicing. Hybridisation of nusinersen to ISS-N1 within pre-mRNA causes more frequent inclusion of
exon 7 in mature SMN2 transcripts, leading to an increase in the production of full-length SMN protein. Nusinersen is FDA- and EMA- approved for the treatment of
SMA. (B) IONIS-SOD1Rx specifically targets a 20 nucleotide-long sequence within exon 1 of SOD1, resulting in binding to both pre-mRNA and mature RNA causing
inhibition of wild-type and mutant SOD1 expression. ALS patients are currently being recruited for a phase Ib/IIa trial of IONIS-SOD1Rx.
provided enough evidence in mid-2016 that nusinersen caused
statistically significant improvements in motor function (Finkel
et al., 2017), prompting submission to the FDA of the new drug
application. Interim analyses from a second phase III trial with
type II SMA patients called CHERISH (NCT02292537) and an
open-label study in pre-symptomatic infants named NURTURE
(NCT02386553) have also proven encouraging.
A second gene therapy called AVXS-101 (a.k.a.
scAAV9.CB.SMN and ChariSMA), which delivers the SMN1
gene using non-replicating self-complementary adeno-associated
virus serotype 9 (scAAV9), has also shown significant pre-clinical
potential (Mulcahy et al., 2014). A major advantage of this
therapy over nusinersen is that AAV9 can cross the BBB in mice,
cats, and non-human primates, permitting intravenous delivery
(Duque et al., 2009; Foust et al., 2009; Samaranch et al., 2012).
Moreover, AAV9 displays neuronal tropism and can mediate
stable, long-term expression with a single administration, which
is important given immunogenicity issues associated with viruses
(Lorain et al., 2008). This contrasts with the multiple, invasive
intrathecal injections of nusinersen, which can have adverse
side effects (Haché et al., 2016). Marketed by AveXis, AVXS-101
has completed testing in type I SMA patients in an open-label,
dose-escalation phase I clinical trial (NCT02122952). The
treatment is safe and well tolerated, and caused improvements
in survival, attainment of motor milestones, and motor function
when compared with historical SMA type I cohorts (Mendell
et al., 2017). Two further open-label phase III trials with type
I patients in the US and EU are planned. SMN1 expression is
driven by a hybrid cytomegalovirus enhancer/chicken β-actin
(CAG) promoter, and AVXS-101 is being injected intravenously.
ALS: A Gene Therapy on the Horizon?
No drugs are currently being tested in late-stage clinical trials
for ALS, and until recently, the only FDA-/EMA-approved
drug for the disease was the orally available Riluzole, which
prolongs patient survival by ≈3 months (Bellingham, 2011).
Riluzole can influence ion channel function, neurotransmission,
and growth factor secretion, but inhibition of glutamate release
from pre-synaptic nerve terminals counteracting motor neuron
excitotoxicity appears to be the most disease-relevant benefit
(Bellingham, 2011). In May 2017, the FDA surprisingly approved
Edaravone (a.k.a. MCI-186 and Radicava), which is a free radical
scavenger shown to modestly slow symptom progression in
SOD1G93A mice (Ito et al., 2008). In an open-label phase II study
without comparator arm involving 19 ALS patients, intravenous
administration of Edaravone was shown to be safe and reduce
oxidative stress (Yoshino and Kimura, 2006); however, in a
subsequent double-blind, placebo-controlled study, drug efficacy
was not demonstrated (Abe et al., 2014). Nevertheless, a phase III
trial with narrow inclusion criteria showed Edaravone modestly
delayed disease progression in a limited subset of ALS patients
(Writing Group and Edaravone (MCI-186) ALS 19 Study Group,
2017). Edaravone is unlikely to be effective in a wider ALS
population and there is a sizeable administration burden, limiting
excitement for the drug (Hardiman and van den Berg, 2017).
Palliative care incorporating dietary and respiratory support,
speech and language therapy, and specialist physiotherapy can
also improve survival in ALS (Martin et al., 2017b), and
provides arguably a greater benefit to quality of life than current
pharmaceutical intervention (Hardiman et al., 2011).
In over 20 years since the approval of Riluzole, more than 20
additional compounds have been tested in over 50 randomized,
controlled trials, involving in excess of 13,000 ALS patients,
with little clinical success (Mitsumoto et al., 2014; Petrov et al.,
2017). Consistent with ALS complexity, the tested drugs possess
a broad range of proposed mechanisms of action, including
anti-inflammation and anti-oxidation. Rather than targeting the
underlying genetics, these compounds were trialled for their
ability to support the ailing ALS nervous system and restrict the
insidious progression of disease. These unsuccessful therapeutics
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include three neurotrophic factors delivered as recombinant
proteins - BDNF, CNTF, and insulin-like growth factor-1 (IGF-
1) (Bartus and Johnson, 2017a). Also known as neurotrophins,
neurotrophic factors are target-secreted (e.g., from muscles)
proteins essential for the growth, development and survival
of several nerve types, including motor neurons (Huang and
Reichardt, 2001). Delivering neurotrophins has been pursued as
a therapy for ALS because their expression can decline with time
in models and patients (Krakora et al., 2012). While injection of
recombinant proteins is not gene therapy per se, when adapted
for delivery by viruses, these and other neurotrophic factors have
shown promising results in pre-clinical ALS models (Henriques
et al., 2010; Nizzardo et al., 2012) (Table 1). Additionally,
intramuscular injections of plasmids encoding multiple isoforms
of hepatocyte growth factor (HGF, drug named VM202) or
a transcription factor able to increase expression of vascular
endothelial growth factor (VEGF, drug named SB-509) have been
trialled in ALS patients (Scarrott et al., 2015). Both plasmids
had favorable safety profiles in phase I/II studies (VM202,
NCT02039401 and SB-509, NCT00748501) (Sufit et al., 2017),
but whether these drugs will be tested further remains unclear
(Scarrott et al., 2015).
Without detailed knowledge of disease etiology and
underlying cellular pathologies, neuroprotection is potentially
the only viable method for tackling a complex syndrome
like ALS. However, with increased understanding of gain-
and loss-of-function mechanisms of genetic forms of ALS, a
second category of knockdown gene therapies encompassing
ASOs and RNAi has emerged. These have principally been
tested in SOD1, but also C9ORF72, rodent models (Table 2).
These oligonucleotide-mediated therapeutics are designed to
specifically target and reduce levels of toxic, mutant proteins
(e.g., C9ORF72, SOD1, TDP-43, FUS) and are showing
promise in mice. While they may have a narrow applicability
window due to small percentages of genetically determined
ALS, given pathological commonalities, such as cytoplasmic
TDP-43 sequestration (Neumann et al., 2006) and possible
involvement of wild-type SOD1 misfolding in disease (Bosco
et al., 2010), there is scope for broader application. Moreover,
many sALS patients possess mutations in genes linked to fALS.
Targeting the cause of disease in this manner is likely to have
the greatest therapeutic impact, and obviates the requirement
for co-treatment of multiple downstream pathways. The ASO
IONIS-SOD1Rx (a.k.a. ISIS 333611 and BIIB067) targets both
wild-type and mutant SOD1 mRNA for degradation (Figure 2B).
Importantly for this strategy, Sod1 knockout mice develop
normally and do not show motor neuron loss, although their
response to axonal injury is impaired (Reaume et al., 1996), and
there is evidence that SOD1 loss-of-function may modify ALS
severity (Saccon et al., 2013). IONIS-SOD1Rx administration
into CSF of SOD1G93A rats resulted in reduced SOD1 protein
in spinal cord (Winer et al., 2013). IONIS-SOD1Rx was thus
tested in 24 ALS patients in a randomized, placebo-controlled
phase I trial (Miller et al., 2013). In this first-in-human clinical
study of intrathecal ASO delivery, ≈12 h infusion of IONIS-
SOD1Rx was shown to be safe and well tolerated. A phase Ib/IIa
trial (NCT02623699) is currently recruiting ALS patients to
further evaluate safety, tolerability, and pharmacokinetics of
IONIS-SOD1Rx.
SMA GENE THERAPY LESSONS FOR
ALS
There are numerous possible intersecting explanations for the
plethora of failed ALS clinical trials (Mitsumoto et al., 2014),
not limited to (1) most pre-clinical research has been conducted
in SOD1G93A mice, which do not accurately model the entire
ALS spectrum; (2) poor experimental design and execution of
pre-clinical work (Scott et al., 2008); (3) focusing on mouse
survival as an indicator of drug potential (Genç and Özdinler,
2014); (4) pharmacological issues such as insufficient dose or
access/bioavailability to targeted tissue; (5) timing of intervention
(Benatar, 2007); (6) patient heterogeneity, poor trial stratification,
and scarcity of biomarkers; and (7) incomplete understanding of
disease mechanism(s).
Similar difficulties have, at least partially, been overcome by
the SMA research community in order for nusinersen to receive
regulatory approval. Being a monogenic condition, treating SMA
is undoubtedly simpler than the challenge posed by the broad-
ranging heterogeneity of ALS. Nonetheless, the clinical approval
of nusinersen was a significant milestone not just for SMA, but
gene therapy as a whole. That is not to say that the job is complete
for SMA, as the clinical response to nusinersen is wide-ranging
and includes non-responders (Finkel et al., 2017). However, over
the last decade, a great deal has been learnt from the pre-clinical
development of SMA gene therapies and the clinical trials of
nusinersen and AVXS-101. Given the clinical and mechanistic
overlap between the diseases, these lessons learned from SMA
may be useful for ALS, particularly when considering the array
of gene therapies pre-clinically tested in ALS rodent models
(Tables 1, 2) and thus likely to be in the clinical drug pipeline. We
have therefore summarised this information to emphasize some
key points for ALS gene therapy development.
Careful Therapeutic Targeting Is
Required
A clear understanding of where a therapy is needed is mandatory
for clinical success. SMA is primarily a LMN disorder; however,
in severe cases, pervasive pathology has been reported. For
instance, congenital heart problems (Rudnik-Schöneborn et al.,
2008), bone complications (Khatri et al., 2008), and vascular
defects (Somers et al., 2016) are known to occur in some type
I SMA patients. Cell intrinsic SMN depletion causes similar
and additional pathologies in mice (Hamilton and Gillingwater,
2013). A sliding scale of vulnerability to SMN reduction has
therefore been suggested; at one end, LMNs are the first cell type
disturbed by diminished SMN, and as levels are decreased further,
more cell types and tissues become affected (Sleigh et al., 2011).
This appears to be the case in mouse models, but may be sub-
clinical in the majority of SMA patients, as non-motor neuronal
involvement is less common. Nevertheless, concerns persist that
treating SMA patients with nusinersen, which is delivered directly
to the CSF to target LMNs, may alter disease trajectory and reveal
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novel pathologies caused by chronic SMN deficiency outside the
CNS (Tizzano and Finkel, 2017).
There is thus discussion, for both ASOs and viruses, as to
which single delivery route provides the best therapeutic outcome
for SMA (Hua et al., 2011; Glascock et al., 2012b; Porensky
et al., 2012; Nizzardo et al., 2014; Zhou et al., 2015). Major
determinants of this are the BBB and the BSCB, which not only
restrict access of systemically delivered therapies to the brain and
spinal cord, but can also confine drugs within the CNS when
directly administered. Targeting therapies to NMJs for uptake
and retrograde transport along motor axons can circumvent
these barriers (Tosolini et al., 2013; Mohan et al., 2014; Tosolini
and Morris, 2016), but this is compromised by denervation.
Nonetheless, once inside the CNS, ASOs are able to distribute
widely (Rigo et al., 2014). Accordingly, intracerebroventricular
injection of SMN ASOs results in robust SMN upregulation
in the CNS (Hua et al., 2010; Passini et al., 2011; Porensky
et al., 2012; Rigo et al., 2014), while intravenous or subcutaneous
administration triggers a more systemic increase outside the CNS
(Hua et al., 2011; Keil et al., 2014). Viral vectors are better
than ASOs at overcoming BBB permeability problems (Foust
et al., 2010; Valori et al., 2010; Dominguez et al., 2011; Meyer
et al., 2015), but distinctions in therapeutic outcome between
routes still apply (Glascock et al., 2012a,b). In addition, modifying
the delivery speed of intrathecal injections can alter AAV
tropism; slower injections (i.e., over 8 min) result in preferential
transduction of the spinal cord, whereas faster injections (i.e.,
over 30 s) preferably transduce the brain and peripheral tissue
(Li et al., 2017). Notwithstanding, there remains little doubt
that using multiple injection modes to provide body-wide SMN
augmentation provides the best phenotypic rescue in SMA mice
(Nizzardo et al., 2014; Osman et al., 2014), while limiting the
onset of delayed, non-neuronal pathologies such as tail necrosis
(Foust et al., 2010; Dominguez et al., 2011). The importance of
careful therapeutic targeting of SMN to all required cells has
been confirmed using numerous transgenic mice where SMN has
been overexpressed in SMA models in a tissue-specific fashion
(Gogliotti et al., 2012; Martinez et al., 2012).
Cautious selection of administration route is not the only way
to affect the voyage of gene therapy through the body. A number
of additional therapy-dependent tactics can be employed to
optimize delivery. Despite limited packaging capacity (≈4.5 kb
for single-stranded and ≈2.4 kb for self-complementary AAV),
AAV has become the most promising vector for gene delivery in
neurological disease; it establishes stable nuclear episomes, thus
reducing the risk of integrating into the host genome and causing
insertional mutagenesis, it can transduce both dividing and non-
mitotic cells, and it maintains exogenous gene expression for
extended periods (Murlidharan et al., 2014). With approximately
twice the capacity of AAV, LV has also been employed as a
proof-of-concept vector in pre-clinical models of SMA (Azzouz
et al., 2004a) and ALS (Tables 1, 2); however, given that LV can
randomly insert into the host genome, there are major safety
issues associated with its clinical application (Imbert et al., 2017).
The advantages of AAV led to scAAV9 being chosen for SMN1
delivery in the AveXis gene therapy, AVXS-101. AAV serotypes
possess divergent capsid proteins that bind to distinct host cell
surface receptors and co-receptors, thereby determining the cells
a virus can transduce (i.e., the tropism) and how efficiently it
can spread (Murlidharan et al., 2014). Multiple AAV serotypes
have been used in SMA mice (Foust et al., 2010; Passini et al.,
2010; Tsai et al., 2012), but serotype 9 was selected for AVXS-
101 because of its comparatively strong tropism toward LMNs
throughout the spinal cord in a range of species (Foust et al., 2009;
Bevan et al., 2011; Federici et al., 2012). While numerous AAV
serotypes and administration routes have also been tested in ALS
mice (Tables 1, 2), it remains unclear which serotype will prove to
be most effective. AAV9 and AAVrh10 are good candidates, but
natural and engineered serotypes have recently been identified
with improved tropism toward ALS-pertinent tissues (Deverman
et al., 2016; Chan et al., 2017). Viral transgene expression can
also be restricted using promoters with selective and defined
expression patterns (Kügler, 2016). Combining knowledge of
viral tropism with promoter selectivity thus provides a potential
method for exquisite, cell type-specific targeting (von Jonquieres
et al., 2013). Disease state (Chen et al., 2012) and age (Foust
et al., 2009; Tosolini and Morris, 2016) also impact viral tropism,
likely through alterations in host cell receptor availability, while
promoter usage likewise changes with pathology and time; hence,
it will be vital to test permutations of virus serotype/promoter
in relevant pre-clinical models of ALS throughout all stages of
disease.
Unlike AAV, ASOs do not readily penetrate tissues, while
their cellular uptake and transition to the nucleus, their site of
action, is limited. Indeed, it is estimated that <1% of ASOs
reach their desired target, as the majority distribute to unwanted
organs such as the liver (Godfrey et al., 2017). This mandates
repeated therapeutic injections that can cause adverse events
(Haché et al., 2016) and toxic ASO accumulation (Godfrey
et al., 2017). Consequently, several chemical modifications to
the ASO phosphate backbone have been tested and shown to
improve safety and pharmacological properties (Evers et al.,
2015). Moreover, a number of drug distribution systems
compatible with systemic delivery are being developed that
enhance ASO transport to disease-pertinent tissues and therefore
ease administration and reduce the required dose. These ASO
vectorisation strategies can be divided into (1) viral approaches
that use harmless, non-replicating viruses, such as AAV, and
(2) non-viral strategies that utilise different positively charged
molecules such as lipids or peptides (Lehto et al., 2012).
Viruses present immunogenicity issues and are not suitable for
all nucleic acid-based molecules; nevertheless, to aid cellular
targeting and cytoplasm-to-nucleus transport, viral vectors have
been engineered to encode modified snRNAs that incorporate
specific ASO sequences. Once inside target cells, these ASOs
are imported into the nucleus where they accumulate as part of
snRNPs (Imbert et al., 2017). When packaged into viral vectors,
snRNAs containing ASOs targeting SMN2 have shown potential
for SMA (Meyer et al., 2009; Dal Mas et al., 2015; Odermatt
et al., 2016). As has the non-viral approach of conjugating
ASOs to CPPs (Hammond et al., 2016; Shabanpoor et al., 2017).
CPPs are 5–30 amino acid long, positively charged peptides
that transport various macromolecules across cell membranes
(Lehto et al., 2012). Highlighting the significance of therapeutic
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targeting, intravenous injection of an SMN2 SSO conjugated to a
CNS-targeting CPP caused the greatest extension in SMA mouse
survival reported to date – from 12 to 456 days compared to only
54 days for the “naked” oligonucleotide (Hammond et al., 2016).
Importantly, these CPP-oligonucleotides are capable of delivery
to the CNS of both neonatal and adult mice (Hammond et al.,
2016; Shabanpoor et al., 2017); however, the safety, tolerability,
and pharmacokinetics of CPP-conjugated ASOs are yet to be
tested in additional organisms.
AAV and LV have separately been combined with RNAi-
based strategies for SOD1 knockdown (Table 2), but only
recently have ASO vectorisation strategies been tried in ALS
models. Compared with non-encapsulated oligonucleotides,
loading SOD1-specific ASOs into lipid particles caused a much
greater reduction in SOD1 protein in HEK293 cells (Chen
et al., 2017). Moreover, direct intravascular delivery of non-ASO-
loaded nanoparticles resulted in brain accumulation in wild-
type zebrafish, indicating promise for future work in ALS mice
(Chen et al., 2017). SOD1 pre-mRNA-targeting ASOs were also
embedded in modified snRNAs and engineered into AAVrh10,
which was then co-injected into the blood and brain of SOD1G93A
mice either at birth or pre-symptomatically at 50 days (Biferi
et al., 2017). The ASO skips SOD1 exon 2 generating a premature
stop codon, which resulted in ≈70% reduction of SOD1 protein
levels in the spinal cord 112 days post-perinatal administration.
The gene therapy caused vast improvements in neuromuscular
function, restricted weight loss, and, when given early, resulted
in the greatest SOD1G93A survival extension yet reported to
≈250 days (Biferi et al., 2017).
Amyotrophic lateral sclerosis patients and models do not
show the same cell and tissue vulnerability-resistance continuum
as SMA; however, it is clear that pathology is not limited
to LMNs and UMNs, probably contributing to the gamut of
unsuccessful ALS clinical trials (Bartus and Johnson, 2017a).
Indeed, the ALS/FTD clinicopathological overlap (Morita et al.,
2006; Neumann et al., 2006; Vance et al., 2006) has been
replicated in ALS mice, indicating the importance of cortical
cells and synapses to the disease (Fogarty et al., 2015, 2016).
Furthermore, the non-cell autonomous toxicities emanating from
cells such as microglia (Puentes et al., 2016), and the prion-
like cell-to-cell spread of pathological aggregates, also indicate
that targeting therapies to motor neurons as well as additional
cells and tissues is likely to be required in order to generate
meaningful improvements in ALS prognosis. Indeed, disease
onset and mortality are delayed in mutant SOD1 mice when
microglial activation is pharmacologically restricted prior to
disease onset (Kriz et al., 2002; van den Bosch et al., 2002),
while disease progression is slowed in mutant SOD1 mice in
which SOD1 is removed from microglia, oligodendrocytes, or
astrocytes (Boillée et al., 2006; Yamanaka et al., 2008; Kang et al.,
2013). Moreover, expression of mutant SOD1 in motor neurons
alone is insufficient to fully recapitulate the mutant SOD1 mouse
phenotype (Lino et al., 2002; Pramatarova et al., 2001), while
deletion of SOD1 from motor neurons and interneurons of
SOD1 mutant mice only delays disease onset (Wang et al.,
2009).
Spinal muscular atrophy research has highlighted the
importance of comparing different therapy injection sites and
testing novel technologies to improve targeting of therapeutics
not only to the required tissues, but also to the correct
resident cells and subcellular locations. Viral targeting of rapidly
dividing cells affected by ALS (e.g., astrocytes), subtleties in
motor neuron subtype vulnerability (Nijssen et al., 2017), along
with the indication that different subcellular motor neuron
compartments, such as the NMJ, may require differential support
and treatment (Moloney et al., 2014), add to the complexity of
the challenge ahead. It is therefore imperative that during ALS
therapy design, careful consideration is given to what cells and
tissues need to be targeted and how exactly this can be most
effectively achieved.
Combinatorial Treatment Is Key
It is conceivable that carefully crafted gene therapy combinations
targeting multiple disease mechanisms could provide additive
effects in MNDs. Indeed, AAV1-follistatin treatment significantly
boosted muscle and body weight of SMA mice suboptimally
dosed with SMN2 ASO (Feng et al., 2016), while in isolation,
follistatin upregulation or myostatin reduction have little effect
(Sumner et al., 2009; Rindt et al., 2012). Co-delivery of
recombinant follistatin with an SMN2-inducing compound also
resulted in a small additive enhancement in motor function,
but not survival (Harris and Butchbach, 2015). Similarly, genetic
upregulation of SMA modifier plastin 3 has no effect on untreated
SMA mouse lifespan (Ackermann et al., 2013), but can drastically
improve survival in ASO-dosed animals (Hosseinibarkooie
et al., 2016). A range of other pathological mechanisms could
be concomitantly targeted in SMA (Bowerman et al., 2017).
Combinations of drugs directed at just the SMN pathway have
also proven more effective than individual treatments (Kwon
et al., 2011; Liu et al., 2013), while the impact of ASOs targeting
SMN2 has been enhanced by co-treatment with a compound
(Osman et al., 2017), co-targeting the SMN2-repressing long
non-coding RNA, SMN-AS1, for ASO-mediated knockdown
(d’Ydewalle et al., 2017; Woo et al., 2017), and co-masking
additional negative SMN2 splicing elements (Pao et al., 2013).
Furthermore, a holistic approach to treatment appears to be
important, as providing nutritional support to SMA mice can
advance therapeutic efficacy (Narver et al., 2008; Butchbach et al.,
2014).
These SMA studies suggest that previously unsuccessful
therapeutics may provide additive benefits when used in
combination, highlighting the importance of simultaneously
treating multiple disease pathways. Given the pathology observed
in ALS, it will also be vital to co-modify pathways in different
cell types. To facilitate this, viral vectors engineered with
selective promoters could be united with CPP-conjugated ASOs
in order to synergistically target multiple genes in related and
independent pathways across distinct and highly specific cell
populations. This was recently confirmed in mutant SOD1G93A
mice by concomitantly targeting distinct disease mechanisms in
motor neurons, astrocytes and microglia (Frakes et al., 2017).
In isolation, genetic suppression of the NF-κB pathway in
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microglia or shRNA-mediated knockdown of SOD1 in motor
neurons and astrocytes via systemic AAV9 administration
resulted in similar improvements in survival, disease onset, and
progression of mutant SOD1 mice. However, the combined
targeting of these two pathomechanisms across three major
cell types resulted in an additive amelioration in all assessed
phenotypes. The median mutant lifespan was expanded from
137 to 188 days with a maximum survival of 204 days,
which is one of the best extensions reported to date (Frakes
et al., 2017). In a separate study, joint lentiviral targeting of
three distinct disease pathways aiming to reduce excitotoxicity
resulted in a synergistic neuroprotective effect in SOD1G93A mice
(Benkler et al., 2016), while simultaneous delivery of multiple
neurotrophic factors can also induce modest additive effects
over individual therapies (Haase et al., 1997; Krakora et al.,
2013; Dadon-Nachum et al., 2015), although not consistently
(Dodge et al., 2010). Like SMA, it is thus clear that prognosis
can be improved in ALS models by attempting a multifaceted
gene therapy approach. It is somewhat surprising that there
have not yet been any published studies that test concurrent
delivery of neuroprotective and knockdown strategies in vivo
for ALS. ASO-mediated depletion of toxic mutant proteins
is likely to be most critical in ALS, and should be joined
with a gamut of neuroprotective accessory therapies such as
neurotrophic factors (Henriques et al., 2010), SMN upregulation
(e.g., via nusinersen or AVXS-101) (Kariya et al., 2012; Turner
et al., 2014), and preservation of NMJ innervation (Miyoshi
et al., 2017), in order to determine the most efficacious drug
combinations.
Consider Dose Number and Drug
Concentrations
In addition to delivering gene therapies to the intended cellular
and subcellular site(s), effectors must be expressed/released at a
therapeutically viable concentration. Providing multiple SMN2
ASO doses results in greater phenotypic amelioration in SMA
mice (Hua et al., 2011; Zhou et al., 2015; Hammond et al.,
2016), while increased concentrations of ASOs or AAVs have
a similar positive effect (Meyer et al., 2015; Hammond et al.,
2016; Hosseinibarkooie et al., 2016). These results unsurprisingly
indicate that delivering greater quantities of therapy, results in
higher SMN upregulation, and therefore a better phenotypic
rescue of SMA mice. There will inevitably be a point at which
SMN overexpression becomes detrimental to cells; however, two-
fold genetic overexpression of SMN in the nervous system of
control mice appears to be safe (Turner et al., 2014; Perera
et al., 2016). Nevertheless, this may not be the case for all genes
(Denovan-Wright et al., 2008), and thus care must be taken when
artificially increasing protein abundance, especially considering
that secreted proteins can elicit autocrine and paracrine effects
(Baumgartner and Shine, 1997).
Caution must also be exercised with target gene reduction
strategies as there may be disparate, time-dependent
consequences between protein reduction below a physiological
threshold and complete absence (Rossi et al., 2015). That being
said, toxicities associated with ASO or AAV accumulation
are likely to arise before viability is perturbed by excessive
modulation of a gene. Hence, there is a fine balance between
administering sufficient gene therapy to ensure correct
targeting in effective quantities without causing systemic
toxic accumulation and adverse side effects. Upon intravenous
injection, ASOs accumulate in the liver, kidneys, and lymph
nodes, amongst other places, and can cause hybridisation-
independent toxicities (Godfrey et al., 2017), while AAVs
can become similarly enriched (Zincarelli et al., 2008). The
methods to enhance delivery to disease-susceptible cells and
tissues discussed above (e.g., ASO-CPP conjugation) will
undoubtedly aid in this battle, and should be optimized in ALS
mice, along with ASO chemistries, to enrich the appropriately
targeted therapeutic load. Moreover, multiple ASO doses and
increasing concentrations of gene therapies must be tested
in relevant models to identify the most effective and safe
therapeutic regimes. Due to the immune response, repeated
AAV dosing is not practical (although immunomodulation is
an option) (Lorain et al., 2008), but ASOs can be administered
at multiple time points. However, ASO concentration must also
be optimized to escape host immune responses (Wang et al.,
2008). It should also be remembered that once an AAV has
been delivered, relatively little can be done to regulate transgene
expression, but ASOs can be neutralized by sequestration using
complimentary decoy ASOs (Rigo et al., 2014; Hua et al.,
2015).
Therapeutic Timing Is Critical
As disease progresses, the number of impacted proteins and
processes will likely increase as a result of time as pathways
diverge from the initial cause of pathology. This provides
a rationale for why selectively targeting individual disease
pathways toward the end of a cascade may provide only
limited benefit. Moreover, the greater the duration over which
a disease develops, the more anatomical, circuit, and cellular
damage will ensue leading to greater loss-of-function and
thus a more significant challenge of recovery (Ramírez-Jarquín
et al., 2014; Bartus and Johnson, 2017b). For example, early
NMJ denervation followed by LMN die-back will severely,
if not totally, restrict the ability of the LMN to respond to
extracellular neurotrophic signaling. The successful treatment of
any disorder is thus more likely to occur when a therapy is
administered during early pathogenesis rather than at later time
points and, in particular, at disease end stage. Whilst intuitive,
this highlights the importance of earlier diagnosis, especially
for ALS.
Indeed, the earlier SMN levels are augmented in SMA mice
via SMN gene therapy, the better the therapeutic outcome
(Foust et al., 2010; Hua et al., 2010, 2011; Porensky et al.,
2012; Bogdanik et al., 2015; Zhou et al., 2015). Age-dependent
differences in BBB permeability, neuropil density, and cell
tropisms may contribute (Foust et al., 2009, 2010); however,
the early temporal requirement for SMN has been corroborated
using mice with inducible SMN alleles (Le et al., 2011; Lutz
et al., 2011; Kariya et al., 2014a), and is consistent with
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human and mouse SMN being most highly expressed in the
CNS perinatally (Jablonka and Sendtner, 2017), and the most
common and severe form of SMA (type I) manifesting before
6 months of age. Accordingly, artificially reducing SMN levels
in young adult mice has fewer repercussions than when SMN
is diminished at earlier time points (Le et al., 2011; Kariya
et al., 2014a). All of this suggests that there is a therapeutic
window of opportunity during early development in which
SMN gene therapy is likely to have the greatest chance of
success. One study indicates that in mice, the postnatal window
of highest SMN requirement coincides with neuromuscular
maturation, and that NMJ disruption causes SMN upregulation
in motor neurons (Kariya et al., 2014a). Accordingly, nusinersen
is being tested in the open-label NURTURE trial in pre-
symptomatic newborns genetically diagnosed with SMA. Interim
analyses appear promising, and when complete are likely to
provide compelling evidence of the importance of treating
SMA as early as possible. It is perhaps for this reason, that
a number of small molecule drugs that have proven useful
in SMA mice dosed from birth, have failed in clinical trials
in which patients are treated post-symptom onset (Fuller
et al., 2010). Nevertheless, post-symptomatic restoration of
SMN using an inducible allele has been shown to reverse
overt neuromuscular pathology and significantly improve SMA
mouse lifespan (Lutz et al., 2011). This was corroborated
using systemic administration of SMN2-targeting ASOs in a
mild SMA mouse model (Bogdanik et al., 2015), and in
SMA mice sub-optimally dosed with a small molecule SMN2
splice-modifying drug and subsequently re-treated with the
same compound or AAV1-follistatin gene therapy (Feng et al.,
2016).
Early therapeutic interventions in mutant SOD1 mice also
often result in greater impact on disease. For example, pre-
symptomatic injection of VEGF-expressing LV into SOD1G93A
mouse muscles resulted in greater delay in disease onset and
progression compared to injection at paralysis onset (Azzouz
et al., 2004b). The same is true for AAV-mediated IGF-1 delivery
(Kaspar et al., 2003) and SOD1 silencing (Foust et al., 2013;
Biferi et al., 2017), and recombinant VEGF injections into
the brain of mutant SOD1 rats (Storkebaum et al., 2005).
Significantly, these studies show, like in SMA, that survival of
mutant SOD1 rodents can be extended even when therapies
are delivered post-symptomatically. There is also evidence
to indicate that treatment during the perinatal stage (e.g.,
postnatal day 1, P1) can cause even greater improvements
in SOD1G93A lifespan (Foust et al., 2013; Biferi et al., 2017),
perhaps due in part to sub-clinical embryonic/perinatal defects
(van Zundert et al., 2012) and differential age-dependent
gene therapy tropism (Foust et al., 2009); however, testing
intervention timing in these models needs to be therapeutically
appropriate, as ALS is an adult-onset neurodegenerative disease
currently with no biomarkers. The pre-symptomatic treatment
of fALS patients with a known ALS-causing genetic mutation
is a possibility, in the same vein as SMA patients in the
NURTURE trial of nusinersen, but treatment in humans at
an age akin to P1 is highly unlikely. Nevertheless, perinatal
therapy administration paradigms provide useful proof-of-
concept information, and are invaluable in gene therapy
optimisation.
Amyotrophic lateral sclerosis greatly impacts the neuro-
muscular system and its proteome, which could cause disease-
specific, time-constrained alterations that affect therapeutic
efficacy; for instance, viral tropism could be impacted through
differential receptor expression (Tosolini and Morris, 2016).
Rodent work indicates that there is likely to be an optimal
period for ALS therapy delivery, but with a broader therapeutic
window, in which disease progression can at least be slowed,
if not halted or even partially reversed. It is therefore
paramount that potential therapeutics are tested at a range of
time points in ALS rodents and in large animals including
non-human primates in order to improve therapeutic timing
strategy.
CONCLUSION
Typified by extensive heterogeneity, the ALS disease spectrum
poses a daunting challenge for developing effective treatments.
This diversity, along with numerous other factors, has resulted
in an overabundance of unsuccessful clinical trials. Many of
these involved compounds targeting likely secondary pathogenic
pathways with only limited therapeutic potential. However, over
the last two decades, gene therapy using ASOs or viral vectors
have emerged as the most promising strategy for treating nervous
system disorders. The predominantly LMN disease SMA has
benefited from this burgeoning field, with the recent regulatory
approval of the ASO nusinersen. Through developing ASO- and
virus-mediated drugs for SMA, much has been learnt about gene
therapy design and development that could help to alleviate the
impact of other MNDs. Pre-clinical SMA research has made it
clear that gene therapies must be efficiently delivered to pertinent
sites of pathology, at concentrations within the therapeutic
range, and at appropriate times in order to increase the chances
of success. Tantamount to this is the parallel modification of
multiple disease pathways across cell and tissue types. Similar
conclusions are also beginning to emerge from pre-clinical
ALS models. It is thus by no coincidence that the greatest
amelioration of the SOD1G93A mouse phenotype to date was
driven by the combined targeting of two pathomechanisms across
multiple cell types, and the dual-administration of an AAV-
guided SOD1-specific ASO into the blood and brain. Given the
current lack of diagnostic and prognostic biomarkers for ALS
and reliance upon the SOD1G93A mouse, successful translation
to patients will be tricky. Nevertheless, by considering issues
outlined in this review and thinking clearly about treatment
logistics, a viable ALS gene therapy is unlikely to be far from the
clinic.
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